"Analyst valuations
Following the positive Phase 3 trial results in December, the analysts covering Neuren significantly increased their current risk-adjusted valuations, with the range now $5.05 to $7.70 per share. In addition, Neuren was selected by Bioshares as one of the “Top 6 Picks for 2022” and was added to its model portfolio."
Ann: Q4 2021 quarterly activity and cash flow report, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |